Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.

ABSTRACT:

Background

Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes.

Objective

To identify SEA sub-phenotypes with differential responsiveness to benralizumab.

Methods

One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensitization status, blood eosinophil count, IgE levels, FEV₁ % predicted, n

SUBMITTER: Di Bona D 

PROVIDER: S-EPMC9293293 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature